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Background: Classic Kaposi Sarcoma (KS) is vascular sarcoma, known to be more common in Mediterranean elderly
men and characterized by an indolent clinical behavior. To our knowledge, this is the first evidence in literature,
describing a spontaneous partial regression in a non-HIV, non-iatrogenic KS.
Case presentation: A 68-years old woman, presenting with weight loss and respiratory symptoms, was diagnosed with
a classic KS involving lungs and mediastinal lymph nodes. No skin or mucosal lesions were identified, HIV positivity was
ruled out. Due to patient’s choice, she was kept under surveillance with 3-monthly thorax-abdomen-pelvis computed
tomography scan (TAP CT). A first reassessment proved progressive disease (PD) associated with symptoms worsening. A
new TAP CT, performed at 5 months from the diagnosis, showed stable disease (SD), with a minor reduction in size of
mediastinal lymphadenopathies. A further reassessment, performed 5 months later, resulted in a partial response (PR)
despite the absence of any medical treatment. Up to date, the disease is in remission, patient is asymptomatic and still on
surveillance.
Conclusion: Given the possible indolent behaviour of KS, we believe that close surveillance can represent a valuable
approach in selected cases.
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KS is a locally aggressive endothelial tumour belonging
to the family of vascular sarcoma. According to aetiology
and epidemiology, four variants have been described:
classic KS, usually affecting Mediterranean elderly men;
endemic African KS, common in middle-aged adults and
children in Equatorial Africa; iatrogenic KS, usually occur-
ring in solid organ transplant recipients but also in patients
receiving immunosuppressive treatment (i.e. corticosteroid)
for a long time; acquired immunodeficiency syndrome as-
sociated KS, the most aggressive variant, affecting human
immunodeficiency virus (HIV) positive patients. KS is in-
variably associated with human herpes virus type 8 (HHV-
8), which seems to play a key role in KS pathogenesis [1].
KS typically presents with mucocutaneous lesions, mostly
affecting lower extremities, face, trunk, genitalia and oro-
pharyngeal mucosa, but it can also involve lymph nodes
and visceral organs, including the respiratory and* Correspondence: a.frezza@unicampus.it
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lent, especially in the classic variant.
Pulmonary involvement is common in critically immu-
nodeficient patients, occurring approximately in 45% of
those with cutaneous AIDS-related KS with previous or
concomitant mucocutaneous lesions. Lung metastases
from sporadic KS are rare, especially in female and
pediatric series with a distinct male predominance [3].
Treatment options for non-HIV forms include chemo-
therapy (liposomal doxorubicin, vinblastine, taxanes) [4],
immunotherapy (interferon alpha, interleukin-12) and
anti-HHV8 therapy [5]. Close surveillance can also be a
possibility in selected cases.
Case presentation
A 68-years old woman, with no previous medical history,
presented with severe weight loss, shortness of breath
and cough (ECOG PS: 2). A chest x-ray followed by a
thorax-abdomen-pelvis computed tomography (TAP
CT) showed the presence of a 53 mm large mass in the
left lower lobe (LLL) with pericardial involvment and a
30 × 18 mm large lesion with similar morphological fea-
tures in the upper lobe of the left lung. Multiple bilaterall. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Baseline thorax-abdomen-pelvis computed tomography,
showing a large mass in the left lower lobe, multiple bilateral
pulmonary nodules and mediastinal adenophaties.
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were also reported (Figure 1). Bronchoscopic and CT-
guided biopsies were attempted without success, ending up
with a surgical exploration and complete removal of one
lung nodule. Pathology proved a malignant stromal tumor
with endothelial phenotype, consistent with a pulmonary
localization of KS. Immunohistochemistry resulted positive
for CD31, CD 34 and HHV-8; Ki67 10% (Figure 2). Physical
examination ruled out any suspicious skin lesions, while
upper gastrointestinal endoscopy and colonoscopy ex-
cluded mucosal localizations. Anti-HIV antibody and HIV
antigen tests were both negative.Figure 2 Histology and immunohistochemistry (CD31, CD34 and HHV-8).Given patient’s refusal of any medical treatment, she
was started on a surveillance program. The first re-
assessment proved PD according to RECIST 1.1 criteria,
with the appearance of a new nodule in the right mid
lobe (RML), an increase in size of the known lesion in
the LLL (60 mm) and a stability of the carinal lymph-
nodes (Figure 3). Despite the persistence of symptoms,
due to patient’s choice, no treatment was started. A new
radiological assessment, performed after 5 months from
diagnosis, showed a minor reduction in size of the
lymphadenopathies and an almost complete resolution
of the nodule in the RML. Given radiological evidence of
disease regression and improvement in symptoms, the
patient underwent a further TAP CT five months later,
showing PR, with a reduction in number of lung nodules
and reduction in size on both the lesion in the LLL and
carinal lymphnodes (Figure 4). Up to date, at nineteen
months from diagnosis, disease is still in remission with
stable pulmonary nodules and no evidence of systemic
spread, in absence of any medical treatment. The patient
is still on surveillance through three-monthly clinical as-
sessment and six-monthly TAP CT, asymptomatic,
ECOG PS: 0.
Conclusion
Spontaneous regression of KS has been previously de-
scribed in the iatrogenic type. Interruption of corticoste-
roids [6], systemic immunosuppressive drugs [7,8], and
ACE-inhibitors [9] can lead to a spontaneous self-
healing of KS skin lesions. In AIDS-related subtype,
Figure 3 Thorax-abdomen-pelvis computed tomography two
months after diagnosis, showing progressive disease.
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retroviral therapy [10,11]. To our knowledge, this is the
first evidence in literature, describing a spontaneous
partial regression in non-HIV, non-iatrogenic Kaposi
sarcoma. In Kondo’s paper [12], multiple skin lesion his-
tologically suspected for sporadic Kaposi sarcoma, disap-
peared after the discontinuation of a prolonged steroid
therapy administered for chronic respiratory failure. In
the present case report, no trigger mechanisms leading
to the development of this disease were identified, nor
removable stimuli to malignant proliferation. There are
no data in literature providing evidence for possible bio-
logical mechanism underlying this spontaneous regres-
sion of disease. Conversely, the presence of herpes virus
infection and any concomitant changes in the balance of
immune system are well recognized factors promoting
the development of this cancer [13-16]. Therefore, we
might assume that a fully competent immune system, in
absence of the impairment induced by chemotherapy ad-
ministration, could have played a role in the observedFigure 4 Thorax-abdomen-pelvis computed tomography two
months after diagnosis, showing partial response.disease regression. However, future studies are needed to
verify the reliability of this hypothesis and, despite this
interesting observation, more data are needed to support
close surveillance as a management strategy in this rare
disease.
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RML: Right mid lobe; SD: Stable disease according to RECIST 1.1 criteria; TAP
TC: Thorax-abdomen-pelvis computed tomography scan.
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